BridgePoint Medical, a developer of catheter-based system for treating coronary chronic total occlusions (CT's), has signed a definitive agreement to be acquired by Boston Scientific.
The proprietary catheter-based system featuring a CrossBoss CTO crossing catheter and a Stingray CTO re-entry system is designed to navigate through occluded coronary arteries for permitting blood circulation to reach critical areas of the heart.
New York-Presbyterian Hospital University Medical Center interventional vascular therapy center director Marty Leon said the CTO system provides physicians an important treatment option for treating difficult cases of arterial blockages.
"Many of these patients would have previously been referred for bypass surgery, typically requiring weeks of recovery," Leon added.
"Now, many of them are able to go home within 24 hours."
The terms of Boston Scientific’s deal with BridgePoint have not been disclosed.
Boston Scientific chief executive officer Hank Kucheman said, "We believe the BridgePoint coronary devices will provide the Boston Scientific Interventional Cardiology business a dedicated CTO solution while the Boston Scientific Peripheral Intervention business offers the TruePath CTO Device and OffRoad CTO Device."
The acquisition, which is subject to customary closing conditions, is expected to be completed in the fourth quarter of 2012.